Ovulation induction with oral contraception alone in biochemical to overt primary ovarian insufficiency: a pilot study.

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500111618

Enrollment

Unknown

Registered

2025-11-03

Start date

2025-11-05

Completion date

Unknown

Last updated

2025-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

premature ovarian insufficiency

Interventions

Group OC:Yaz (drospirenone/ethinylestradiol) will be administered from day 3 until the trigger day, at a dosage of 1 tablet daily.

Eligibility

Sex/Gender

Female

Age

25 Years to 50 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Women presenting with oligomenorrhea, a baseline FSH level greater than 20 IU/L, and a transvaginal ultrasound showing antral follicular count (AFC) of fewer than 2.

Exclusion criteria

Exclusion criteria: Exclusion criteria: resistant ovary syndrome, medical history of cancer therapy, systemic lupus erythematosus, adenomyoma, intrauterine adhesion, or a venous thromboembolism risk assessment score of 4 or higher.

Design outcomes

Primary

Measure	Time frame
the number of oocyte retrieved;	—

Secondary

Measure	Time frame
the number of 2PN;the number of cryopreserved embryos;the clinical pregnancy rate following FET cycles;	—

Countries

China

Contacts

Public ContactZhang Qiong

Xiangya Hospital, Central South University

chuangq@csu.edu.cn+86 137 8722 4913

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026